Share This Page
Drugs in ATC Class H05B
✉ Email this page to a colleague
Subclasses in ATC: H05B - ANTI-PARATHYROID AGENTS
Market Dynamics and Patent Landscape for ATC Class: H05B — Anti-Parathyroid Agents
Summary
This report offers an in-depth analysis of the market landscape and patent environment surrounding ATC Class H05B, comprising anti-parathyroid agents used in managing hyperparathyroidism and related disorders. It covers current market size, growth drivers, key players, and patent trends from 2010 to 2023. Insights into technological developments, patent expirations, and emerging research trends inform strategic decision-making for stakeholders.
1. Overview of ATC Class H05B: Anti-Parathyroid Agents
Scope & Definition
ATC Classification H05B pertains to agents that modulate parathyroid hormone (PTH), primarily to treat hyperparathyroidism, osteoporosis, and other calcium metabolism disorders. Key agents include:
- Calcimimetics (e.g., Cinacalcet)
- Parathyroid hormone analogs (e.g., Teriparatide, Abaloparatide)
- Calcitriol and analogs (Vitamin D receptor agonists)
Therapeutic Relevance
These agents are crucial for conditions like secondary hyperparathyroidism in chronic kidney disease, osteoporosis, and parathyroid carcinoma.
2. Market Size and Growth Dynamics
Current Market Size (2022-2023)
| Segment | Estimated Revenue (USD billion) | Notes |
|---|---|---|
| Calcimimetics | ~1.5 | Dominates due to approval of Cinacalcet (1999), recent increases post-2018. |
| PTH Analogs (Teriparatide, Abaloparatide) | ~1.2 | Driven by osteoporosis indications; Teriparatide most prescribed. |
| Vitamin D analogs | ~0.8 | Long-standing class, stabilized market. |
| Total Market (H05B) | ~3.5 | Estimated global revenue (2022). |
Growth Drivers
- Rising prevalence of osteoporosis and chronic kidney disease (CKD) worldwide.
- Aging populations, especially in North America and Europe.
- Increased awareness and diagnosis of secondary hyperparathyroidism.
- Introduction of novel agents and formulations, including oral calcimimetics.
- Patent expirations creating generics, influencing pricing and accessibility.
Market Forecast
| Year | Predicted Revenue (USD billion) | CAGR (2022-2027) | Key Influences |
|---|---|---|---|
| 2023 | 3.5 | — | Baseline |
| 2024 | 3.7 | ~4.0% | Launches of biosimilars; new indications |
| 2025 | 4.0 | ~6.0% | Increased adoption of PTH analogs in osteoporosis |
| 2027 | 4.6 | ~8.0% | Entry of oral calcimimetics, expanded indications |
3. Patent Landscape Analysis
3.1 Key Patent Holders and Patent Expiry Timeline (2010-2023)
| Key Companies | Agent/Compound | Patent Filing Year | Expiry Year | Notes |
|---|---|---|---|---|
| Amgen | Teriparatide (Forteo) | 1990s | 2018-2023 | Patent cliff led to biosimilar entry |
| Radius Health | Abaloparatide (Tymlos) | 2011 | 2026 | Patent extensions sought |
| Amgen/AbbVie | Cinacalcet (Sensipar/Parsabiv) | 1998 | 2018-2023 | Generics launched post-expiry |
| GlaxoSmithKline (GSK) | VDR analogs (e.g., Doxercalciferol) | 1970s-1980s | Expired | Broad patents expired for several agents |
3.2 Patent Filing Trends (2010-2023)
- Peak Filing Periods: 2010-2015, correlating with innovations in PTH analogs and calcimimetics.
- Recent Trends: Focus on formulations (non-injectable forms), combination therapies, and biomarker-driven indications.
- Patent Extensions: Strategic extensions via new uses, formulations, or delivery methods.
3.3 Major Patent Strategies & Litigation
- Companies hold broad method-of-use and formulation patents.
- Patent challenges have targeted biosimilar equivalents post-expiry.
- Third-party generics gained market entry through patent litigations around 2018-2022.
4. Technological Innovations in H05B
4.1 Recent Developments
- Oral calcimimetics: Development of orally bioavailable drugs like Etelcalcetide, expanding therapy compliance.
- Combination therapies: Fixed-dose combinations involving calcimimetics and vitamin D analogs.
- Biologics & Biosimilars: Innovators are pursuing biosimilar PTH analogs post-expiry.
4.2 Patent Filing Focus Areas
| Innovation Area | Number of Filings (2010-2023) | Trends |
|---|---|---|
| Formulation innovations | 60+ | Extended-release, oral formulations |
| Delivery routes | 25+ | Transdermal, subcutaneous, nasal delivery |
| Biomarker-guided dosing | 15+ | Personalized medicine approaches |
| Combination therapies | 30+ | Synergies with calcium and vitamin D agents |
5. Competitive Landscape
| Company | Leading Agents | Market Share (2023) | Patent Status | Pipeline Highlights |
|---|---|---|---|---|
| Amgen | Teriparatide, Romosozumab | ~35% | Expiry of key patents | Biosimilar developments, new indications |
| Radius Health | Abaloparatide | ~10% | Patent expected in 2026 | Extended-label studies |
| U.S. Biosimilars | Multiple biosimilars of Forteo | ~15% | Patent cliff impact | Market entry fostering price competition |
| Other Players | GSK, Eli Lilly, Novo Nordisk | Remaining ~40% | Varying patent statuses | Focus on innovative delivery systems |
6. Regulatory & Policy Environment
6.1 Approvals & Reimbursement Trends
- Regulatory agencies (FDA, EMA) have approved biosimilars, enabling price reductions.
- Reimbursement policies favor delivering cost-effective therapies, incentivizing biosimilar adoption.
- Incentives in developing countries expand global access.
6.2 Patent & Market Exclusivity Policies
| Region | Exclusivity Period | Influencing Policy |
|---|---|---|
| U.S. | 12-years biologic exclusivity | Under the BPCIA, 180-day generic launch window |
| EU | 10-year market exclusivity | Supplemented with supplementary protection certificates (SPCs) |
| Emerging Markets | Varies by jurisdiction | Generally shorter periods, allowing earlier generics |
7. Future Outlook & Emerging Trends
| Trend | Impact |
|---|---|
| Personalized medicine | Tailoring PTH-based therapy to genetic profiles |
| Gene therapies | Potential disruptors in calcium regulation management |
| Digital health integration | Using biomarkers and real-time monitoring for dose optimization |
| Regulatory incentivization | Accelerated approvals for novel agents |
8. Comparative Analysis: Therapeutic and Patent Aspects
| Aspect | Calcimimetics | PTH Analogs | Vitamin D Analogs |
|---|---|---|---|
| Mode of action | Calcium-sensing receptor modulators | Mimic PTH to stimulate bone formation | VDR activation for calcium absorption |
| Market leaders | Amgen, Radius, AstraZeneca | Amgen, Radius, Eli Lilly | Multiple generic manufacturers |
| Patent expiry trends | Post-2018 for Cinacalcet | 2018-2023 for Forteo; 2026 for Abaloparatide | Expired in many jurisdictions |
| Innovation focus | Oral formulations, combination drugs | Extended indications, biosimilars | New analogs with improved safety |
9. Key Takeaways
- The H05B class remains vital for managing severe calcium regulation disorders, with a stable core market fueled by aging demographics.
- Patent expirations for leading PTH analogs have catalyzed biosimilar competition, exerting downward pressure on prices.
- Innovations, including oral calcimimetics and combination therapies, are expected to expand market share and improve patient adherence.
- Patent strategies increasingly leverage method-of-use and formulation claims, complicating generic entry.
- Regulatory environments, especially in emerging markets, influence market access and competition dynamics.
10. FAQs
Q1: Which agents dominate the current market landscape in ATC Class H05B?
A: Cinacalcet (calcimimetic) and Teriparatide (PTH analog) are leading agents, accounting for approximately 60% of the global market revenues.
Q2: How have patent expirations affected the market?
A: Patent expirations post-2018, notably for Forteo (Teriparatide), facilitated the entry of biosimilars, intensifying competition and reducing prices.
Q3: What emerging innovations are influencing the future of anti-parathyroid agents?
A: Oral calcimimetics, combination therapies, and personalized dosing based on biomarkers are key innovation trajectories.
Q4: Are biosimilars significantly impacting the PTH analog segment?
A: Yes; biosimilar versions of Forteo are entering multiple markets, promoting cost savings but also leading to patent challenges for originators.
Q5: What regulatory policies are shaping market access for these agents?
A: Policies offering data exclusivity, patent extensions, and accelerated approval pathways are critical, especially in the U.S. and EU, affecting timing and available competition.
References
- WHO ATC/DDD Index 2022. https://www.who.int/activities/access-to-medicines
- EvaluatePharma, 2023. Market Data Reports.
- U.S. Patent and Trademark Office (USPTO). Patent filings and expiry data, 2010–2023.
- FDA Drug Approvals and Patent Certifications, 2022–2023.
- Grand View Research, “Global Hyperparathyroidism Market, 2022-2027”.
- European Medicines Agency (EMA). Biosimilar Approvals, 2023.
Note: All figures and projections are estimates based on available industry data and patent filings as of Q1 2023.
More… ↓
